Gene Therapy Trial at the Retina Foundation of the Southwest featured in The Dallas Morning News
Mason Two Crow, 22, first came to the Retina Foundation in 2003 with a diagnosis of X-linked retinoschisis, a rare genetic condition affecting the retina. Two years ago he came in for a follow-up appointment where he learned that he had the opportunity to be one of the very first to ever be enrolled in a gene therapy trial for his rare eye disease. Mason gives credit to the research scientists at the Retina Foundation for gifting him with the hope that a cure for X-linked retinoschisis may be on the horizon. Click here to read more of Mason’s incredible story on www.dallasnews.com.
Related ArticlesNew Technology Gives ‘Second Sight’ to the Blind Healthier Eyesight through Smarter Eating is Proven Research Measuring the Release of A Therapeutic Drug in a Controlled Lab Setting First Patient in Phase 1/2 Clinical Study of Gene Therapy is Treated for X-Linked RP Choroideremia Research Is Necessary to Help Prevent Blindness at an Early Age